Overview

Safety and Efficacy of Topical NVC-422 Gel in Impetigo

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind study comparing 0.1% NVC-422, 0.5% NVC-422 and 1.5% NVC-422 topical gel in children with impetigo.
Phase:
Phase 2
Details
Lead Sponsor:
NovaBay Pharmaceuticals, Inc.
Collaborators:
International Dermatology Research
International Dermatology Research, Inc.
Novum Pharmaceutical Research Services